Hematology & Oncology
With the wide range of new and exciting targeted therapies under development, clinical research in hematology and oncology continues to be the most rapidly growing areas of focus for small to mid-sized companies. Moving beyond traditional chemotherapy approaches, the industry has advanced to leveraging innovative biomarkers in combination with targeted therapies to provide more personalized treatments, and in some instances attack the underlying causes of disease process.
CRMG understands the complexities involved with oncology research programs including the nuances involved with early stage development. We provide our sponsors with therapeutically experienced teams that consist of both clinical operations and medical professionals who have years of experience conducting oncology clinical studies.
Further, we leverage our strong relationships and strategic collaborations with various consultants and disease-specific consortiums such as the National Comprehensive Cancer Network (NCCN®) to provide our clients with access to the most respected oncology researchers across a wide variety of different cancers. Together with our partners, we ensure that our clients receive sound advice on protocol design at the outset. To that end, your study will be initiated on time, conducted according to protocol, and as importantly, always kept on track.
With experience across a variety of cancers/tumor types, the CRMG team has supported clinical trials in recent years in the following:
- Breast cancer
- Hematologic cancers
- Malignant melanoma
- Anaplastic astrocytoma (AA)
- Anaplastic oligodendroglioma (AO)
- Anaplastic mixed oligo-astrocytoma (AOA)
- Glioblastoma multiforme (GBM)
- Gliosarcoma (GS)
In addition, CRMG has experience in assisting innovative efforts in cutting-edge technologies such as photodynamic therapy to address multiple forms of skin cancer.